FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2094731114> ?p ?o ?g. }

• W2094731114 endingPage "251" @default.
• W2094731114 startingPage "246" @default.
• W2094731114 abstract "Objective: To determine the efficacy and toxicity of oral topotecan and paclitaxel in untreated patients with extensive stage small cell lung cancer (SCLC). Patients and Methods: Thirty-eight patients received 1.75 mg/m2 of oral topotecan days 1 to 5 and 175 mg/m2 paclitaxel IV over 3 hours on day 5 (after topotecan) every 4 weeks for 6 cycles. Subcutaneous G-CSF at a dose of 5 μg/kg was then given 24 to 48 hours after the last dose of chemotherapy and daily for 10 days. Results: All 38 patients were available for toxicity and response analysis. A median of 5 treatment cycles was given, with a range of 1 to 7 cycles. Seventeen (45%) patients received at least 6 cycles of treatment. The most common severe adverse events were neutropenia (42.1%), leukopenia (34.2%), thrombocytopenia (18.4%), nausea (18.4%), diarrhea (13.2%), and fatigue (13.2%). Two grade 5 treatment-related evens were seen. The median overall survival was 9.1 month (95% CI: 7.5–13.0 months), with a 1-year survival estimate of 44.7% (95% CI: 31.4–63.7%) and a 2-year survival rate of 5.3% (95% CI: 1.4–20.3%). The median time to progression was 5.0 months (95% CI: 3.8–6.6 months), with a 1-year progression-free rate of 5.8% (95% CI: 1.5–22.2%) and a 2-year progression-free rate of 2.9% (95% CI: 0.4–19.9%). The estimated confirmed response rate was 52.9%. Conclusion: This regimen has shown similar antitumor activity to that achieved with standard therapy. Because of unacceptable toxicity and cost, we do not recommend this regimen in a palliative setting." @default.
• W2094731114 created "2016-06-24" @default.
• W2094731114 creator A5004590681 @default.
• W2094731114 creator A5008026182 @default.
• W2094731114 creator A5021990576 @default.
• W2094731114 creator A5038755935 @default.
• W2094731114 creator A5040261194 @default.
• W2094731114 creator A5058147268 @default.
• W2094731114 creator A5071847625 @default.
• W2094731114 creator A5075047537 @default.
• W2094731114 creator A5081957836 @default.
• W2094731114 creator A5091518312 @default.
• W2094731114 date "2006-06-01" @default.
• W2094731114 modified "2023-09-27" @default.
• W2094731114 title "Phase II NCCTG Trial of Oral Topotecan and Paclitaxel With G-CSF (Filgrastim) Support in Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer" @default.
• W2094731114 cites W1796184815 @default.
• W2094731114 cites W1859729923 @default.
• W2094731114 cites W1919288105 @default.
• W2094731114 cites W1932169383 @default.
• W2094731114 cites W1981534406 @default.
• W2094731114 cites W2012797500 @default.
• W2094731114 cites W2029409133 @default.
• W2094731114 cites W2037357429 @default.
• W2094731114 cites W2037605675 @default.
• W2094731114 cites W2060661492 @default.
• W2094731114 cites W2068466600 @default.
• W2094731114 cites W2073898802 @default.
• W2094731114 cites W2097597328 @default.
• W2094731114 cites W2099756452 @default.
• W2094731114 cites W2111309259 @default.
• W2094731114 cites W2169249953 @default.
• W2094731114 cites W2180665179 @default.
• W2094731114 cites W2253216568 @default.
• W2094731114 cites W2270187459 @default.
• W2094731114 cites W2329673293 @default.
• W2094731114 cites W4255152173 @default.
• W2094731114 cites W4293241248 @default.
• W2094731114 doi "https://doi.org/10.1097/01.coc.0000217566.11742.b5" @default.
• W2094731114 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16755177" @default.
• W2094731114 hasPublicationYear "2006" @default.
• W2094731114 type Work @default.
• W2094731114 sameAs 2094731114 @default.
• W2094731114 citedByCount "6" @default.
• W2094731114 crossrefType "journal-article" @default.
• W2094731114 hasAuthorship W2094731114A5004590681 @default.
• W2094731114 hasAuthorship W2094731114A5008026182 @default.
• W2094731114 hasAuthorship W2094731114A5021990576 @default.
• W2094731114 hasAuthorship W2094731114A5038755935 @default.
• W2094731114 hasAuthorship W2094731114A5040261194 @default.
• W2094731114 hasAuthorship W2094731114A5058147268 @default.
• W2094731114 hasAuthorship W2094731114A5071847625 @default.
• W2094731114 hasAuthorship W2094731114A5075047537 @default.
• W2094731114 hasAuthorship W2094731114A5081957836 @default.
• W2094731114 hasAuthorship W2094731114A5091518312 @default.
• W2094731114 hasConcept C126322002 @default.
• W2094731114 hasConcept C141071460 @default.
• W2094731114 hasConcept C2776256026 @default.
• W2094731114 hasConcept C2776283816 @default.
• W2094731114 hasConcept C2776694085 @default.
• W2094731114 hasConcept C2777063308 @default.
• W2094731114 hasConcept C2779171977 @default.
• W2094731114 hasConcept C2780580376 @default.
• W2094731114 hasConcept C2780873365 @default.
• W2094731114 hasConcept C2781209748 @default.
• W2094731114 hasConcept C29730261 @default.
• W2094731114 hasConcept C71924100 @default.
• W2094731114 hasConcept C90924648 @default.
• W2094731114 hasConceptScore W2094731114C126322002 @default.
• W2094731114 hasConceptScore W2094731114C141071460 @default.
• W2094731114 hasConceptScore W2094731114C2776256026 @default.
• W2094731114 hasConceptScore W2094731114C2776283816 @default.
• W2094731114 hasConceptScore W2094731114C2776694085 @default.
• W2094731114 hasConceptScore W2094731114C2777063308 @default.
• W2094731114 hasConceptScore W2094731114C2779171977 @default.
• W2094731114 hasConceptScore W2094731114C2780580376 @default.
• W2094731114 hasConceptScore W2094731114C2780873365 @default.
• W2094731114 hasConceptScore W2094731114C2781209748 @default.
• W2094731114 hasConceptScore W2094731114C29730261 @default.
• W2094731114 hasConceptScore W2094731114C71924100 @default.
• W2094731114 hasConceptScore W2094731114C90924648 @default.
• W2094731114 hasIssue "3" @default.
• W2094731114 hasLocation W20947311141 @default.
• W2094731114 hasLocation W20947311142 @default.
• W2094731114 hasOpenAccess W2094731114 @default.
• W2094731114 hasPrimaryLocation W20947311141 @default.
• W2094731114 hasRelatedWork W180056525 @default.
• W2094731114 hasRelatedWork W1990990694 @default.
• W2094731114 hasRelatedWork W2023120562 @default.
• W2094731114 hasRelatedWork W2094731114 @default.
• W2094731114 hasRelatedWork W2152780528 @default.
• W2094731114 hasRelatedWork W2359878197 @default.
• W2094731114 hasRelatedWork W2389727101 @default.
• W2094731114 hasRelatedWork W2399102665 @default.
• W2094731114 hasRelatedWork W2435362053 @default.
• W2094731114 hasRelatedWork W4281731412 @default.
• W2094731114 hasVolume "29" @default.
• W2094731114 isParatext "false" @default.
• W2094731114 isRetracted "false" @default.

• next